Literature DB >> 19003080

Chemical genomics: massively parallel technologies for rapid lead identification and target validation.

Uli Hacksell1, Norman Nash, Ethan S Burstein, Fabrice Piu, Glenn Croston, Mark R Brann.   

Abstract

Chemical genomics is a new research paradigm with importantapplications in drug discovery. It links genomic targets withsmall-molecule chemistries thereby allowing for efficient targetvalidation and lead compound identification. ACADIA'schemical-genomics platform consists of a large and diverse small-moleculelibrary (800,000), a reference drug library (2,000), druggablegenomic targets (>300) and a cell-based functional assaytechnology (R-SAT(TM); Receptor Selection and AmplificationTechnology) that allows for ultra-high throughput screening(>500,000 data points/week) as well as high throughputpharmacology and profiling over a wide range of targets. Twoexamples are presented that illustrate the success of ourchemical-genomics approach: (i) The validation of inverse agonismat serotonin 5-HT(2A) receptors as an antipsychotic mechanismand the subsequent discovery of potent and selectively acting 5-HT(2A) inverse agonists, currently in preclinical development,and (ii) the discovery of the first ectopically binding subtype-selective muscarinic m1 agonist.

Year:  2002        PMID: 19003080      PMCID: PMC3449916          DOI: 10.1023/A:1021169023731

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  17 in total

Review 1.  Transgenic gene knock-outs: functional genomics and therapeutic target selection.

Authors:  S Harris; S M Foord
Journal:  Pharmacogenomics       Date:  2000-11       Impact factor: 2.533

2.  Too many targets, not enough target validation.

Authors:  D E. Szymkowski
Journal:  Drug Discov Today       Date:  2001-04-01       Impact factor: 7.851

Review 3.  Muscarinic receptor ligands and their therapeutic potential.

Authors:  R M Eglen; A Choppin; M P Dillon; S Hegde
Journal:  Curr Opin Chem Biol       Date:  1999-08       Impact factor: 8.822

Review 4.  The impact of genomics on drug discovery.

Authors:  C Debouck; B Metcalf
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 5.  Pharmacological receptors: a century of discovery--and more.

Authors:  D J Triggle
Journal:  Pharm Acta Helv       Date:  2000-03

Review 6.  Functional cell-based uHTS in chemical genomic drug discovery.

Authors:  Glenn E Croston
Journal:  Trends Biotechnol       Date:  2002-03       Impact factor: 19.536

7.  Discovery of an ectopic activation site on the M(1) muscarinic receptor.

Authors:  Tracy A Spalding; Carol Trotter; Niels Skjaerbaek; Terri L Messier; Erika A Currier; Ethan S Burstein; Donghui Li; Uli Hacksell; Mark R Brann
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

8.  High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells.

Authors:  T L Messier; C M Dorman; H Braüner-Osborne; D Eubanks; M R Brann
Journal:  Pharmacol Toxicol       Date:  1995-05

9.  Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.

Authors:  M D Wood; K L Murkitt; M Ho; J M Watson; F Brown; A J Hunter; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 10.  Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism.

Authors:  T M Willson; S A Jones; J T Moore; S A Kliewer
Journal:  Med Res Rev       Date:  2001-11       Impact factor: 12.944

View more
  2 in total

Review 1.  Chemical genomics for studying parasite gene function and interaction.

Authors:  Jian Li; Jing Yuan; Ken Chih-Chien Cheng; James Inglese; Xin-zhuan Su
Journal:  Trends Parasitol       Date:  2013-11-09

Review 2.  On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Authors:  Uli Hacksell; Ethan S Burstein; Krista McFarland; Roger G Mills; Hilde Williams
Journal:  Neurochem Res       Date:  2014-03-30       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.